Testing a new treatment for pancreatic cancer before surgery
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a new treatment, PTM-101, placed during a laparoscopy procedure for people with pancreatic cancer that can be removed with surgery. It aims to see if adding this treatment before standard chemotherapy helps improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have pancreatic cancer that has not spread and can be potentially removed with surgery.
- You have not had any previous treatment for your pancreatic cancer.
- You are healthy enough for a laparoscopy procedure, with no active infections or other serious medical conditions.
- You do not have another cancer that requires treatment, except for certain early-stage cancers.
- You are not allergic to paclitaxel or the materials in the treatment implant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine (TTI-101) combined with targeted radiation for people with pancreatic cancer that is either borderline or locally advanced. The goal is to see if this combination can shrink or control the cancer better than usual treatments.
This study looks at using a special blood test (ctDNA MRD) to track how well the tumor responds to chemotherapy before surgery for pancreatic cancer. It may help doctors decide if the treatment is working and guide next steps.
This study is looking at genetic material and proteins from pancreatic tumors to understand how the cancer responds to treatment. It aims to help doctors choose the best therapies for patients with certain types of pancreatic cancer that can be removed surgically or that have not spread to other organs.
This trial studies whether adding SBP-101 to standard chemotherapy (gemcitabine plus nab-paclitaxel) can improve outcomes in people with metastatic pancreatic cancer. You may be eligible if you have not yet started treatment for metastatic disease and meet other health and test requirements.
This trial tests a new type of immunotherapy (called Lm-LLO-TT) combined with a standard chemotherapy drug (gemcitabine) for people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this combination is safe and effective.
This study tests an investigational drug (RR001) given after chemotherapy for people with locally advanced pancreatic cancer that hasn't spread. It aims to see if the new treatment is safe and may help shrink tumors that can be reached with a needle injection.
Hear when a new Pancreatic Ductal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.